Transcept won't let Retrophin increase stake in company
This article was originally published in Scrip
Point Richmond, California-based Transcept Pharmaceuticals turned down Retrophin's request to increase its stake in the company from 4.9% ownership to up to 15%, marking another rejected attempt by Retrophin to grab more shares of Transcept.
You may also be interested in...
In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.
Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.